Ocrelizumab (Ocrevus) and Ketamine Therapy | Tovani Health
Ocrevus (Ocrelizumab) — Anti-CD20 monoclonal antibody (MS — relapsing and primary progressive)
Verdict at Tovani Health
Fully compatible; same clean profile as rituximab.
Ocrelizumab and ketamine have no clinically significant interaction. The anti-CD20 mAb of choice for MS (both relapsing-remitting and primary-progressive). IV infusion every 6 months. Same clean biologic profile as rituximab and the other anti-CD20s.
If you take Ocrevus regularly and are considering at-home ketamine therapy, the combination is generally safe at therapeutic doses. This page covers the brief pharmacologic context and what we do at intake.
How Ocrevus interacts with ketamine
Ocrelizumab is a humanized mAb that depletes CD20+ B cells. Cleared by reticuloendothelial system. No CYP interaction with ketamine.
What we do at intake
Continue as scheduled. Tell us your last infusion date.
Bottom line
Ocrelizumab and ketamine have no clinically significant interaction. The anti-CD20 mAb of choice for MS (both relapsing-remitting and primary-progressive). IV infusion every 6 months. Same clean biologic profile as rituximab and the other anti-CD20s.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Ocrevus (Ocrelizumab) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 22, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.